9-((2-phosphonylmethoxy)ethyl)guanine has been researched along with Neoplasms* in 1 studies
1 other study(ies) available for 9-((2-phosphonylmethoxy)ethyl)guanine and Neoplasms
| Article | Year |
|---|---|
Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.
GS-9219, a novel prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethyl) guanine (PMEG) has significant activity as monotherapy in dogs with non-Hodgkin's lymphoma. Phase I trials have been initiated in humans based on the encouraging activity observed in canine lymphoma. Two new analogues of GS-9219 (GS-343074 and GS-424044) were recently produced for evaluation as potential novel antineoplastic agents against solid tumours. As a preclinical step, effect of GS-343074 and GS-424044 were evaluated against ten canine cancer cell lines for antiproliferative effect. Both analogues displayed antiproliferative activity against multiple canine cancer cell lines, although GS-343074 was more potent and of broader spectrum compared to GS-424044. Flow cytometric analysis of cells that experienced growth inhibition support apoptotic death as a mechanism of action for both analogues. On the basis of in vitro results described here, GS-343074 and GS-424044 show promise as novel anticancer agents in canine cancer. Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Flow Cytometry; Guanine; Humans; Inhibitory Concentration 50; Neoplasms; Organophosphorus Compounds | 2015 |